Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Despite its popularity on TikTok, scalp oiling is nothing new. “It has deep cultural roots,” Dr. Kristina Collins, a double-board-certified dermatologist. “They include Ayurvedic traditions ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

The next-generation portfolio advisor is a fan of diversified investing, which means he’s no fan of the Magnificent ...

When you’re craving something sweet, donuts are the perfect treat. However, you may want to stick to Dunkin' or Krispy Kreme.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Penske (PAG) delivered earnings and revenue surprises of 5.04% and 2.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?